Pharmozyme

Executive Summary

Pharmozyme is a US-based biotechnology company founded in 2012 and headquartered in Sunnyvale, California, specializing in genetics and genomics. The company develops and commercializes molecular diagnostic kits, primarily qPCR-based panels for infectious diseases such as urinary tract infections (UTIs) and respiratory pathogens, as well as extraction-free COVID-19 tests. Its core innovation is a proprietary enzyme manufacturing process designed to eliminate bacterial DNA contamination in PCR reagents, which could improve assay sensitivity and reliability. Despite a focused product pipeline and a novel technology platform, the company remains private with no disclosed funding, valuation, or revenue data, indicating an early-stage profile with limited commercial traction.

Upcoming Catalysts (preview)

• TBDFDA 510(k) clearance for expanded UTI or respiratory panel30% success
• TBDStrategic partnership or licensing deal for enzyme technology25% success